TY - JOUR
T1 - Real-world treatment costs of first-line treatment for metastatic colorectal cancer
T2 - a survey of the JCOG colorectal cancer study group
AU - Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG)
AU - Takashima, Atsuo
AU - Ishiguro, Megumi
AU - Sasaki, Keita
AU - Machida, Ryunosuke
AU - Nagashima, Fumio
AU - Imaizumi, Jun
AU - Hamaguchi, Tetsuya
AU - Yamamoto, Yoshiyuki
AU - Masuishi, Toshiki
AU - Asayama, Masako
AU - Ueno, Hideki
AU - Shinozaki, Katsunori
AU - Kudo, Toshihiro
AU - Machida, Nozomu
AU - Matsuoka, Hiroshi
AU - Ishida, Hideyuki
AU - Yamaguchi, Toshifumi
AU - Nogami, Hitoshi
AU - Yamada, Takeshi
AU - Takegawa, Naoki
AU - Kito, Yosuke
AU - Tonoike, Yuko
AU - Sawada, Ryoichi
AU - Tsukamoto, Shunsuke
AU - Kanemitsu, Yukihide
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press. All rights reserved.
PY - 2024/10/1
Y1 - 2024/10/1
N2 - Background: Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. Methods: We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (<500 000 JPY/month). Results: The study included 1880 participants, 24% of whom were ≥ 75 years. Molecular targeted containing regimens were received by 78% of the patients. The most frequently used regimen was the doublet regimen (fluoropyrimidine with either oxaliplatin or irinotecan) plus bevacizumab (43%), followed by doublet plus cetuximab or panitumumab (21%). The cost of molecular targeted drugs-containing regimens (ranging from 85 406 to 843 602 JPY/month) is much higher than that of only cytotoxic drug regimens (ranging from 17 672 to 51 004 JPY/month). About 16% received high-cost treatments that included panitumumab-containing regimens and pembrolizumab (17% of patients aged ≤74 years and 11% of patients aged ≥75 years). Conclusion: About 16% of mCRC patients received first-line treatment with regimens costing >500 000JPY/month, and molecular targeted drugs being the main drivers of cost.
AB - Background: Although treatment outcomes for metastatic colorectal cancer (mCRC) have dramatically improved over the past few decades, drug costs have also significantly increased. This study aimed to investigate which first-line treatment regimens for mCRC are actually used (frequency) in Japanese practice and at what cost. Methods: We collected data on patients with mCRC who received first-line treatment at 37 institutions of the Japan Clinical Oncology Group Colorectal Cancer Study Group from July 2021 to June 2022, and calculated the cost of regimens. The cost per month of each regimen was estimated based on standard usage, assuming a patient with a weight of 70 kg and a body surface area of 1.8 m2. We categorized the regimens into very high-cost (≥1 000 000 Japanese yen [JPY]/month), high-cost (≥500 000 JPY/month), and others (<500 000 JPY/month). Results: The study included 1880 participants, 24% of whom were ≥ 75 years. Molecular targeted containing regimens were received by 78% of the patients. The most frequently used regimen was the doublet regimen (fluoropyrimidine with either oxaliplatin or irinotecan) plus bevacizumab (43%), followed by doublet plus cetuximab or panitumumab (21%). The cost of molecular targeted drugs-containing regimens (ranging from 85 406 to 843 602 JPY/month) is much higher than that of only cytotoxic drug regimens (ranging from 17 672 to 51 004 JPY/month). About 16% received high-cost treatments that included panitumumab-containing regimens and pembrolizumab (17% of patients aged ≤74 years and 11% of patients aged ≥75 years). Conclusion: About 16% of mCRC patients received first-line treatment with regimens costing >500 000JPY/month, and molecular targeted drugs being the main drivers of cost.
KW - chemotherapy
KW - colorectal cancer
KW - cost of illness
KW - financial toxicity
KW - treatment cost
UR - http://www.scopus.com/inward/record.url?scp=85206017429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85206017429&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyae110
DO - 10.1093/jjco/hyae110
M3 - Article
C2 - 39210583
AN - SCOPUS:85206017429
SN - 0368-2811
VL - 54
SP - 1107
EP - 1114
JO - Japanese journal of clinical oncology
JF - Japanese journal of clinical oncology
IS - 10
ER -